A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB (150 MG) WITH AND WITHOUT A SUBCUTANEOUS LOADING REGIMEN TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY UP TO 2 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

Registry ID

CAIN457F2320

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2015-09-11

Last update

2015-02-13

Conditions

• ANKYLOSING SPONDYLITIS

Related clinical trials

• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TULISOKIBART IN PARTICIPANTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (ANKYLOSING SPONDYLITIS)
• A MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN SUBJECTS WITH ANKYLOSING SPONDYLITIS
• AN EXTENSION STUDY TO EVALUATE THE SUSTAINABILITY OF CLINICAL BENEFITS, SAFETY AND TOLERABILITY OF SECUKINUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

View on source registry